Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

Botox Cosmetic expands beyond face for the first time as FDA approves the anti-wrinkle therapy for treating platysma bands.

The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.